Skip to main content

Morgan Stanley Keeps Their Hold Rating on SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Mon Apr 21, 2025

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $9.00. The company’s shares closed last Thursday at $7.43.

Stay Ahead of the Market:

Purohit covers the Healthcare sector, focusing on stocks such as Genmab, Ascendis Pharma, and Axsome Therapeutics. According to TipRanks, Purohit has an average return of -8.2% and a 33.56% success rate on recommended stocks.

Currently, the analyst consensus on SAGE Therapeutics is a Hold with an average price target of $8.23, a 10.77% upside from current levels. In a report released on April 3, RBC Capital also maintained a Hold rating on the stock with a $7.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $14.97 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.45M.

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).